MedTrace Logo

Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

NCT00708773 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-01-04

No results posted yet for this study

Summary

Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.

Conditions

Interventions

DRUG

Irinotecan

90 minute IV infusion once every 3 weeks. Dose will be based on sex and genotype determination.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Federico Innocenti, MD, PhD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00708773 on ClinicalTrials.gov